A STUDY ON ACUTE TOXICITY, LOCAL IRRITATIVE EFFECT OF AND ALLERGIC RESPONSE TO A NOVEL INTRANASAL MEDICATION CONTAINING THE INTERLEUKIN- 1Β RECEPTOR ANTAGONIST (IL-1RA)


  • B. S. Burlaka Zaporizhzhia State Medical University, Ukraine
  • I. F. Belenichev Zaporizhzhia State Medical University, Ukraine
Keywords: toxicological parameters, allergic response, interleukin-1β receptor antagonist (Il-1Ra)

Abstract

A STUDY ON ACUTE TOXICITY, LOCAL IRRITATIVE EFFECT OF AND ALLERGIC RESPONSE TO A NOVEL INTRANASAL MEDICATION CONTAINING THE INTERLEUKIN- 1Β RECEPTOR ANTAGONIST (IL-1RA)

References

1. Kumar H., Mishra G., Sharma A.K., Gothwal A., Kesharwani P, Gupta U. Intranasal Drug Delivery: A Non-Invasive Approach for the Better Delivery of Neurotherapeutics. Pharm Nanotechnol, 2017 5(3): 203-214. http://dx.doi.org/10.2174/2211738505666170515113936.

2. Agrawal M., Saraf S., Saraf S., Antimisiaris S. G., Chougule M. B., Shoyele S. A., & Alexander A. Nose-to-brain drug delivery: An update on clinical challenges and progress towards approval of anti-Alzheimer drugs. Journal of controlled release : official journal of the Controlled Release Society, 2018, 281: 139–177. https://doi.org/10.1016/j.jconrel.2018.05.011

3. Alshweiat A., Ambrus R., Csoka I. Intranasal Nanoparticulate Systems as Alternative Route of Drug Delivery. Curr Med Chem, 2019;26(35): 6459-6492. doi: 10.2174/0929867326666190827151741. PMID: 31453778.

4. Belenichev I.F., Cherniy V.I., Nagornaya E.A. et all. Neyroprotektsiya i neyroplastichnostʹ [Neuroprotection and Neuroplasticity], 2015, Kiev: Logos: 512. [in Russian].

5. Guidance. Pharmaceutical development (ICH Q8). [Настанова СТ-Н 42-3.0:2011. Лікарські засоби. Фармацевтична розробка (ICH Q8)] Кyiv; 2011. [in Ukrainian]

6. Guidance. Quality risk management (ICH Q9). [Настанова СТ-Н 42-4.2:2011. Лікарські засоби. Управління ризиками для якості (ICH Q9)] Кyiv; 2011. [in Ukrainian].

7. Guidance. Pharmaceutical quality system (ICH Q10). [Настанова СТ-Н 42-4.3:2011. Лікарські засоби. Фармацевтична система якості (ICH Q10)] Кyiv; 2011. [in Ukrainian].

8. Mironov A.N. Rukovodstvo po provedeniyu doklinicheskikh issledovaniy lekarstvennykh sredstv. Chastʹ pervaya [Guidelines for preclinical studies of drugs. Part one], 2012, M. Grif i K: 944. [in Russian].

9. Nastanova. Likarski zasoby. Doklinichni doslidzhennia bezpeky yak pidgruntia klinichnykh vyprobuvan za uchastiu liudyny ta reiestratsii likarskykh zasobiv [Attitude. Medicines. Preclinical safety studies as a basis for human clinical trials and drug registration] (ICH M3(R2)).- ST-N MOZU 42 – 6.0, 2014, Kyiv: 54. [in Ukrainian].

10. Stefanov A.V. Doklinicheskie issledovaniya lekarstvennykh veshchestv [Preclinical studies of drugs], 2000, Kiev, GFTS
Published
2020-09-02
How to Cite
Burlaka, B. S., & Belenichev, I. F. (2020). A STUDY ON ACUTE TOXICITY, LOCAL IRRITATIVE EFFECT OF AND ALLERGIC RESPONSE TO A NOVEL INTRANASAL MEDICATION CONTAINING THE INTERLEUKIN- 1Β RECEPTOR ANTAGONIST (IL-1RA). Biological Markers in Fundamental and Clinical Medicine (scientific Journal), 4(1), 20-23. https://doi.org/10.29256/v.04.01.2020.escbm06